Development of a new and promising antimalarial agent
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
List view / Grid view
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
A previously unknown process by which pathogens breach immune defences offers promise for treating infectious diseases.
Researchers are actively seeking to unravel the intricacies of gene expression regulation throughout the various stages of the P. falciparum lifecycle.
Researchers from Tokyo Tech's World Research Hub Initiative conducted a study to investigate the regulation of gene expression in the apicoplast of the malaria parasite Plasmodium falciparum.
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
Researchers have important implications for the ongoing fight against malaria, a disease that affects approximately 247 million individuals and causes over 619,000 deaths each year, predominantly among young children.
According to US researchers, insights from mouse models of salmonella could lead to better vaccines and immunity.
US researchers outline the development of a new system for testing and developing CRISPR-based gene drives in the laboratory, and safely converting them into tools for potential real-world applications.
Scientists have made a breakthrough in how malaria parasites divide and transmit the disease, a major step forward in preventing one of the biggest killer infections in the world.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.